doi: 10.1161/CIRCINTERVENTIONS.121.010812.
Epub 2021 Jul 20.
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events
Affiliations
- PMID: 34281363
- DOI: 10.1161/CIRCINTERVENTIONS.121.010812
Item in Clipboard
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events
Circ Cardiovasc Interv.
2021 Aug.
Abstract
[Figure: see text].
Trial registration: ClinicalTrials.gov NCT02494895.
Keywords: acute coronary syndrome; ischemia; myocardial infarction; stroke; ticagrelor.
Similar articles
-
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.JAMA Cardiol. 2019 Nov 1;4(11):1092-1101. doi: 10.1001/jamacardio.2019.3355. JAMA Cardiol. 2019. PMID: 31557763 Free PMC article. Clinical Trial.
-
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.Circ Cardiovasc Qual Outcomes. 2020 Aug;13(8):e006660. doi: 10.1161/CIRCOUTCOMES.120.006660. Epub 2020 Jul 30. Circ Cardiovasc Qual Outcomes. 2020. PMID: 32762446
-
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention.Circ Cardiovasc Interv. 2021 Jul;14(7):e010565. doi: 10.1161/CIRCINTERVENTIONS.121.010565. Epub 2021 Jun 16. Circ Cardiovasc Interv. 2021. PMID: 34130477
-
Prolonging Ticagrelor Beyond a Year of Acute Coronary Syndrome: Worth or Harmful?Curr Vasc Pharmacol. 2018;16(5):446-450. doi: 10.2174/1570161116666180117104613. Curr Vasc Pharmacol. 2018. PMID: 29345592 Review.
-
Ticagrelor: a review of its use in adults with acute coronary syndromes.Am J Cardiovasc Drugs. 2015 Feb;15(1):51-68. doi: 10.1007/s40256-015-0108-5. Am J Cardiovasc Drugs. 2015. PMID: 25672642 Review.
Cited by
-
Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial.JAMA Cardiol. 2024 Feb 1;9(2):125-133. doi: 10.1001/jamacardio.2023.4587. JAMA Cardiol. 2024. PMID: 38117483 Clinical Trial.
-
Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review.Pharmgenomics Pers Med. 2023 Nov 3;16:973-990. doi: 10.2147/PGPM.S391400. eCollection 2023. Pharmgenomics Pers Med. 2023. PMID: 37941790 Free PMC article. Review.
-
P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.Sci Rep. 2023 Aug 3;13(1):12608. doi: 10.1038/s41598-023-39213-3. Sci Rep. 2023. PMID: 37537330 Free PMC article.
-
P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention.J Cardiovasc Dev Dis. 2022 Oct 6;9(10):340. doi: 10.3390/jcdd9100340. J Cardiovasc Dev Dis. 2022. PMID: 36286292 Free PMC article. Review.
-
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.EuroIntervention. 2022 Dec 2;18(11):e897-e909. doi: 10.4244/EIJ-D-22-00319. EuroIntervention. 2022. PMID: 35979636 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
